The increased efficacy of the combination treatment in vivo is in line with the in vitro results for UTE10, showing clear activity of both drugs against the FAK and MEK pathways in the western blot data, demonstrating synergism when tumor cells were treated with the drug combinations, as well as with previous published results for mono and combination treatment with avutometinib and defactinib for xenografts of other cancer models, such as lung, uterine carcinosarcoma, and low‐grade ovarian cancer.12, 33, 34. The gene discussed is MAP2K7; the disease is cancer.